Drugs potentially affecting the extent of airways reversibility on pulmonary function testing are frequently consumed despite guidelines
Terry E Jones,1 AnneMarie Southcott,2 Sean Homan3
1Pharmacy Department, The Queen Elizabeth Hospital, Woodville South, SA, 2Respiratory and Sleep Medicine, Western Health, Footscray, VIC, 3Respiratory Unit, The Queen Elizabeth Hospital, Woodville South, SA, Australia
Background: The increase in forced expiratory volume in one second (FEV1) effected by a bronchodilator is routinely assessed when patients undertake pulmonary function testing (PFT). Several drug classes can theoretically affect the magnitude of the increase in FEV1. Withholding periods are advised for many but not all such drugs. Anecdotally, many subjects presenting for PFT are found to have taken drugs that might affect the test. We did an audit of patients presenting for PFT to assess the frequency with which FEV1 reversibility might be affected by drugs.
Methods: One hundred subjects presenting to the laboratory for PFT were questioned about recent drug consumption by an independent pharmacy intern. Reversibility of FEV1 was assumed to have been affected if drugs of interest were consumed within defined withholding periods or two half-lives for drugs without such data.
Results: Sixty-three subjects were prescribed drugs likely to affect FEV1 reversibility. Thirty-six subjects consumed at least one such drug within the withholding period. Half (18) of these patients consumed β-blockers with or without β-agonists. Sixty-five subjects did not recall receiving any advice about withholding drugs prior to the test and only 10 recalled receiving advice from their clinician or pulmonary function technician.
Conclusion: Subjects presenting for PFT are infrequently advised to withhold drugs that may affect FEV1 reversibility, and consequently, often take such drugs close to the time of the test. Therefore, it is likely that the increase in FEV1 is frequently affected by interference from drugs and this might impact on diagnosis and/or treatment options.
Keywords: lung function tests, beta-adrenergic agonists, beta-adrenergic antagonists, withholding periods, bronchodilators
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Readers of this article also read:
Lin SC, Xu YC, Gan ZH, Han K, Hu HY, Yao Y, Huang MZ, Min DL
Published Date: 11 February 2016
Published Date: 28 October 2015
Varghese AM, Saltz LB
Published Date: 15 October 2015
Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M
Published Date: 11 September 2015
Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology
Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, Scartozzi M
Published Date: 22 May 2015
Qin J, Wu SG, Sun JY, Lin HX, He ZY, Li Q
Published Date: 23 April 2015
Brueseke TJ, Tewari KS
Published Date: 23 May 2013
Margarit C, Juliá J, López R, Anton A, Escobar Y, Casas A, Cruz JJ, Galvez R, Mañas A, Zaragozá F
Published Date: 19 November 2012
Cantrell MA, Ruble K
Published Date: 30 May 2011
Gena Kanas, Libby Morimoto, Fionna Mowat, et al
Published Date: 24 February 2010